288 related articles for article (PubMed ID: 26524334)
41. Cell Type-Specific Interferon-γ-mediated Antagonism of KSHV Lytic Replication.
Park MK; Cho H; Roh SW; Kim SJ; Myoung J
Sci Rep; 2019 Feb; 9(1):2372. PubMed ID: 30787356
[TBL] [Abstract][Full Text] [Related]
42. Towards Better Understanding of KSHV Life Cycle: from Transcription and Posttranscriptional Regulations to Pathogenesis.
Yan L; Majerciak V; Zheng ZM; Lan K
Virol Sin; 2019 Apr; 34(2):135-161. PubMed ID: 31025296
[TBL] [Abstract][Full Text] [Related]
43. Intracellular-activated Notch1 can reactivate Kaposi's sarcoma-associated herpesvirus from latency.
Lan K; Murakami M; Choudhuri T; Kuppers DA; Robertson ES
Virology; 2006 Aug; 351(2):393-403. PubMed ID: 16701788
[TBL] [Abstract][Full Text] [Related]
44. Increased efficiency of phorbol ester-induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus during S phase.
McAllister SC; Hansen SG; Messaoudi I; Nikolich-Zugich J; Moses AV
J Virol; 2005 Feb; 79(4):2626-30. PubMed ID: 15681463
[TBL] [Abstract][Full Text] [Related]
45. The pleiotropic effects of Kaposi's sarcoma herpesvirus.
Schulz TF
J Pathol; 2006 Jan; 208(2):187-98. PubMed ID: 16362980
[TBL] [Abstract][Full Text] [Related]
46. Development of an ORF45-Derived Peptide To Inhibit the Sustained RSK Activation and Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus.
Li X; Huang L; Xiao Y; Yao X; Long X; Zhu F; Kuang E
J Virol; 2019 May; 93(10):. PubMed ID: 30842327
[TBL] [Abstract][Full Text] [Related]
47. Antiviral activity of (+)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II.
Xu B; Wang L; González-Molleda L; Wang Y; Xu J; Yuan Y
Antimicrob Agents Chemother; 2014; 58(1):563-73. PubMed ID: 24295975
[TBL] [Abstract][Full Text] [Related]
48. Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus: role of JAK/STAT signaling.
Zeng Y; Zhang X; Huang Z; Cheng L; Yao S; Qin D; Chen X; Tang Q; Lv Z; Zhang L; Lu C
J Virol; 2007 Mar; 81(5):2401-17. PubMed ID: 17151125
[TBL] [Abstract][Full Text] [Related]
49. Minimal reactivation of Kaposi's sarcoma-associated herpesvirus by corticosteroids in latently infected B cell lines.
Zoeteweij JP; Rinderknecht AS; Davis DA; Yarchoan R; Blauvelt A
J Med Virol; 2002 Mar; 66(3):378-83. PubMed ID: 11793390
[TBL] [Abstract][Full Text] [Related]
50. Kaposi's Sarcoma-Associated Herpesvirus ORF21 Enhances the Phosphorylation of MEK and the Infectivity of Progeny Virus.
Yamaguchi T; Watanabe T; Iwaisako Y; Fujimuro M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674756
[TBL] [Abstract][Full Text] [Related]
51. Genotypic and clinicopathological characterization of Kaposi's sarcoma-associated herpesvirus infection in Japan.
Kanno T; Sato Y; Nakamura T; Sakamoto K; Sata T; Katano H
J Med Virol; 2010 Mar; 82(3):400-6. PubMed ID: 20087946
[TBL] [Abstract][Full Text] [Related]
52. The Lymphatic Cell Environment Promotes Kaposi Sarcoma Development by Prox1-Enhanced Productive Lytic Replication of Kaposi Sarcoma Herpes Virus.
Choi D; Park E; Kim KE; Jung E; Seong YJ; Zhao L; Madhavan S; Daghlian G; Lee HH; Daghlian PT; Daghlian S; Bui K; Koh CJ; Wong AK; Cho IT; Hong YK
Cancer Res; 2020 Aug; 80(15):3130-3144. PubMed ID: 32518204
[TBL] [Abstract][Full Text] [Related]
53. Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug.
Nichols LA; Adang LA; Kedes DH
PLoS One; 2011 Jan; 6(1):e14535. PubMed ID: 21264294
[TBL] [Abstract][Full Text] [Related]
54. Hesperetin inhibits KSHV reactivation and is reversed by HIF1α overexpression.
Long WY; Zhao GH; Wu Y
J Gen Virol; 2021 Nov; 102(11):. PubMed ID: 34747688
[TBL] [Abstract][Full Text] [Related]
55. Activation of DNA Damage Response Induced by the Kaposi's Sarcoma-Associated Herpes Virus.
Di Domenico EG; Toma L; Bordignon V; Trento E; D'Agosto G; Cordiali-Fei P; Ensoli F
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27258263
[TBL] [Abstract][Full Text] [Related]
56. Nitric oxide is induced and required for efficient Kaposi's sarcoma-associated herpesvirus lytic replication.
Herrera-Ortíz A; Meng W; Gao SJ
J Med Virol; 2021 Nov; 93(11):6323-6332. PubMed ID: 34297418
[TBL] [Abstract][Full Text] [Related]
57. Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus.
González-Molleda L; Wang Y; Yuan Y
Antimicrob Agents Chemother; 2012 Feb; 56(2):893-902. PubMed ID: 22106228
[TBL] [Abstract][Full Text] [Related]
58. Lytic cycle switches of oncogenic human gammaherpesviruses.
Miller G; El-Guindy A; Countryman J; Ye J; Gradoville L
Adv Cancer Res; 2007; 97():81-109. PubMed ID: 17419942
[TBL] [Abstract][Full Text] [Related]
59. DExD/H Box Helicases DDX24 and DDX49 Inhibit Reactivation of Kaposi's Sarcoma Associated Herpesvirus by Interacting with Viral mRNAs.
Serfecz JC; Hong Y; Gay LA; Shekhar R; Turner PC; Renne R
Viruses; 2022 Sep; 14(10):. PubMed ID: 36298642
[TBL] [Abstract][Full Text] [Related]
60. Histone deacetylase inhibitors induce apoptosis with minimal viral reactivation in cells infected with Kaposi's sarcoma-associated herpesvirus.
Niedermeier A; Talanin N; Chung EJ; Sells RE; Borris DL; Orenstein JM; Trepel JB; Blauvelt A
J Invest Dermatol; 2006 Nov; 126(11):2516-24. PubMed ID: 16810301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
